Autoimmune Diseases  >>  Amjevita (adalimumab-atto)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo
NCT01970475 / 2013-000525-31: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Checkmark For moderate to severe rheumatoid arthritis
Feb 2015 - Feb 2015: For moderate to severe rheumatoid arthritis
Completed
3
526
US, Canada, Europe, RoW
ABP 501, AMJEVITA™, Adalimumab-atto, Adalimumab, HUMIRA®
Amgen
Arthritis, Rheumatoid
11/14
11/14
OLE Study, NCT02114931 / 2013-004654-13: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

Completed
3
467
US, Canada, Europe, RoW
ABP 501, AMJEVITA™, Adalimumab-atto
Amgen
Arthritis, Rheumatoid
04/16
04/16

Download Options